Drug Information

Drug General Information
Drug ID
D0H9WY
Former ID
DNCL002905
Drug Name
PAZ-320
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2 [524644]
Company
Boston Therapeutics
Target and Pathway
Target(s) Maltase-glucoamylase, intestinal Target Info Modulator [544481]
KEGG Pathway Galactose metabolism
Starch and sucrose metabolism
Metabolic pathways
Carbohydrate digestion and absorption
PathWhiz Pathway Starch and Sucrose Metabolism
WikiPathways Metabolism of carbohydrates
References
Ref 524644ClinicalTrials.gov (NCT02060916) Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
Ref 544481Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.